



IN THE CLAIMS:

Please amend the claims as follows:


Claim 1 (original): A method of manufacturing of
7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin of formula I



characterized in that 7-ethyl-10-hydroxycamptothecin of formula II



is subjected to a condensation reaction with 1-chlorocarbonyl-4-piperidinopiperidine hydrochloride of formula III



in a polar aprotic solvent, e.g. in acetonitrile, in the presence of 4-dimethylaminopyridine.

Claim 2 (original): The method according to claim 1, characterized in that 1-chlorocarbonyl--4-piperidinopiperidine hydrochloride is employed in an amount of 1.3 to 3 mol, preferably in an amount of 1.6 to 1.9 mol, per 1 mol of 7-ethyl-10-hydroxycamptothecin.

Claim 3 (currently amended): The method according to ~~any of the preceding claims~~ claim 1, characterized in that 4-dimethylaminopyridine is employed in an amount of 1.5 to 4 mol, preferably in an amount of 1.8 to 2.2 mol, per 1 mol of 7-ethyl-10-hydroxycamptothecin.

Claim 4 (currently amended): The method according to ~~any of the preceding claims~~ claim 1, characterized in that the polar aprotic solvent is employed in an amount of 400 to 600 mol, preferably in an amount of 430 to 460 mol, per 1 mol of 7-ethyl-10-hydroxycamptothecin.

Claim 5 (currently amended): The method according to ~~any of the preceding claims~~ claim 1, characterized in that the condensation reaction is carried out at a temperature of 70 to 80 °C, preferably at a temperature of 73 to 77 °C.